Xenetic Biosciences Inc.

About Xenetic Biosciences Inc.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing proprietary technology platforms for multiple high-value cancer indications, aiming to improve cancer therapies.

Products & Services

DNase I Oncology Platform:An oncology platform designed to improve cancer therapies, targeting multiple indications including pancreatic cancer and other solid tumors.

XBIO-015:A product in the pipeline, specific details not provided in the content.

Specialties

Immune-Oncology Technologies Cancer Therapies Targeting Neutrophil Extracellular Traps (NETs) Pancreatic Cancer Solid Tumors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 4500000 MR: - FA: $4.5 million FAN: 4500000	D: 2025-10-10 FD: 2025-10-10	1 investors

Underwritten Offering Latest

2025-10-10

$4.5M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jonathan Spicer

Associate Professor of Surgery

A

Allan Tsung

Chair of the Department of Surgery and Director of Cancer Therapeutics

M

Matthew Frigault

Medical Oncologist and Assistant Director of the Cellular Therapy Service at Massachusetts General Hospital Cancer Center, Instructor at Harvard Medical School

G

Guenther Koehne

Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology

M

Maksim Mamonkin

Assistant Professor in the Center for Cell and Gene Therapy

G

Grigory G. Borisenko

Non-Executive Director

View 13 more team members with Pro

Unlock Full Team Directory

Recent News